|
|
Prepublished online as a Blood First Edition Paper on March 27, 2003; DOI 10.1182/blood-2002-08-2476.
 Previous Article | Table of Contents | Next Article 
Blood, 15 July 2003, Vol. 102, No. 2, pp. 749-755
TRANSPLANTATION
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
Alessandro M. Gianni,
Michele Magni,
Maurizio Martelli,
Massimo Di Nicola,
Carmelo Carlo-Stella,
Silvana Pilotti,
Alessandro Rambaldi,
Sergio Cortelazzo,
Caterina Patti,
Guido Parvis,
Fabio Benedetti,
Saveria Capria,
Paolo Corradini,
Corrado Tarella, and
Tiziano Barbui
From the Division of Medical Oncology C–Donazione Cristina Gandini, Istituto Nazionale Tumori, Milan; Medical Oncology, University of Milan; Experimental Molecular Pathology Unit, Department of Pathology, Istituto Nazionale Tumori, Milan; Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome; Division of Hematology, Ospedali Riuniti, Bergamo; Division of Hematology, Ospedale Cervello, Palermo; Division of Internal Medicine and Hematology, Ospedale San Luigi, Orbassano, Turin; Institute of Hematology, University of Verona; Department of Hematology, University of Turin; and Division of Hematology, Istituto Nazionale Tumori, and Chair of Hematology I, University of Milan, Italy
Mantle cell lymphoma (MCL) is rarely cured with standard-dose chemotherapy. From January 1997 to February 2000, 28 previously untreated advanced-stage MCL patients younger than 61 years of age were treated at 9 Italian hematologic departments with 3 cycles of standard-dose debulking chemotherapy followed by a high-dose rituximab-supplemented sequence (R-HDS) including intravenous administration of high-dose cyclophosphamide, high-dose cytarabine, high-dose melphalan, and high-dose mitoxantrone plus melphalan. Study end points included toxicity, clinical and molecular response rates, long-term event-free survival (EFS), and overall survival (OS) rates, as well as the ability to harvest tumor-free peripheral blood stem cells. Optimal amounts of polymerase chain reaction–negative (PCR-negative) CD34+ cells were collected from all 20 informative patients. One patient died of toxicity. All 27 patients assessable for response achieved a complete response (CR), of which 24 remain in continuous complete remission (CCR) after a median follow-up of 35 months. Three patients had transient evidence of PCR-detectable disease in the bone marrow. The OS and EFS rates at 54 months were 89% and 79%, respectively. These results compare with the 42% OS rate and the 18% EFS rate observed in 35 age-matched historic controls treated with standard-dose chemotherapy at the participating centers. The use of rituximab in combination with high-dose chemotherapy represents a very effective in vivo purging method. The R-HDS regimen can be safely applied in a multicenter hematology setting and leads to long-term EFS and OS in the majority of patients with an otherwise incurable disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. L. Kasamon, R. J. Jones, R. A. Brodsky, E. J. Fuchs, W. Matsui, L. Luznik, J. D. Powell, A. L. Blackford, A. Goodrich, C. D. Gocke, et al.
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
Ann. Onc.,
October 30, 2009;
(2009)
mdp484v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Andersen, L. B. Pedersen, A. Laurell, E. Elonen, A. Kolstad, A. M. Boesen, L. M. Pedersen, G. F. Lauritzsen, R. Ekanger, H. Nilsson-Ehle, et al.
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
J. Clin. Oncol.,
September 10, 2009;
27(26):
4365 - 4370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Moskowitz and C. H. Moskowitz
Controversies in the Treatment of Lymphoma with Autologous Transplantation
Oncologist,
September 1, 2009;
14(9):
921 - 929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini and E. Zucca
How I treat mantle cell lymphoma
Blood,
August 20, 2009;
114(8):
1469 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al.
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
J. Clin. Oncol.,
March 10, 2009;
27(8):
1209 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, M. Coleman, and J. P. Leonard
Progress in Mantle-Cell Lymphoma
J. Clin. Oncol.,
February 1, 2009;
27(4):
481 - 483.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al.
High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
J. Clin. Oncol.,
November 10, 2008;
26(32):
5175 - 5182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Geisler, A. Kolstad, A. Laurell, N. S. Andersen, L. B. Pedersen, M. Jerkeman, M. Eriksson, M. Nordstrom, E. Kimby, A. M. Boesen, et al.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood,
October 1, 2008;
112(7):
2687 - 2693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui, A. Pileri, M. Boccadoro, F. Ciceri, A. Gallamini, et al.
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey
J. Clin. Oncol.,
July 1, 2008;
26(19):
3166 - 3175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bottcher, M. Ritgen, S. Buske, S. Gesk, W. Klapper, E. Hoster, W. Hiddemann, M. Unterhalt, M. Dreyling, R. Siebert, et al.
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
Haematologica,
April 1, 2008;
93(4):
551 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Kahl
New Therapeutic Strategies for Mantle Cell Lymphoma
ASCO Educational Book,
January 1, 2008;
2008(1):
392 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, A. Guidetti, M. Di Nicola, C. Lavazza, L. Cleris, D. Sia, P. Longoni, M. Milanesi, M. Magni, Z. Nagy, et al.
IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3
Cancer Res.,
April 1, 2007;
67(7):
3269 - 3275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Wannesson, T Panzarella, J Mikhael, and A Keating
Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review
Ann. Onc.,
April 1, 2007;
18(4):
623 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica,
January 1, 2007;
92(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Kahl, W. Longo, J. Eickhoff, J Zehnder, C Jones, J Blank, T McFarland, W Bottner, H Rezazedeh, J Werndli, et al.
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
Ann. Onc.,
September 1, 2006;
17(9):
1418 - 1423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pott, C. Schrader, S. Gesk, L. Harder, M. Tiemann, T. Raff, M. Bruggemann, M. Ritgen, B. Gahn, M. Unterhalt, et al.
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
Blood,
March 15, 2006;
107(6):
2271 - 2278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, M. Di Nicola, M. C. Turco, L. Cleris, C. Lavazza, P. Longoni, M. Milanesi, M. Magni, M. Ammirante, A. Leone, et al.
The Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice
Cancer Res.,
February 1, 2006;
66(3):
1799 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri
Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hematology,
January 1, 2006;
2006(1):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Romaguera, L. Fayad, M. A. Rodriguez, K. R. Broglio, F. B. Hagemeister, B. Pro, P. McLaughlin, A. Younes, F. Samaniego, A. Goy, et al.
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
J. Clin. Oncol.,
October 1, 2005;
23(28):
7013 - 7023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig
Current Treatment Approaches for Mantle-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6409 - 6414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dreyling, G. Lenz, E. Hoster, A. Van Hoof, C. Gisselbrecht, R. Schmits, B. Metzner, L. Truemper, M. Reiser, H. Steinhauer, et al.
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
Blood,
April 1, 2005;
105(7):
2677 - 2684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Hoster, B. Wormann, U. Duhrsen, B. Metzner, H. Eimermacher, A. Neubauer, H. Wandt, H. Steinhauer, et al.
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
J. Clin. Oncol.,
March 20, 2005;
23(9):
1984 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage
Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 20, 2005;
23(3):
461 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini
Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example
Hematology,
January 1, 2005;
2005(1):
321 - 328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Maris, B. M. Sandmaier, B. E. Storer, T. Chauncey, M. J. Stuart, R. T. Maziarz, E. Agura, A. A. Langston, M. Pulsipher, R. Storb, et al.
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
Blood,
December 1, 2004;
104(12):
3535 - 3542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Hoerr, F. Gao, J. Hidalgo, D. Tiwari, K. A. Blum, V. Mathews, D. R. Adkins, W. Blum, S. Devine, R. Vij, et al.
Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
November 15, 2004;
22(22):
4561 - 4566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, W. Vogel, H.-G. Kopp, M. G. Manz, M. Bitzer, G. Schlimok, et al.
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study
Ann. Onc.,
November 1, 2004;
15(11):
1691 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Schiegnitz, R. Forstpointner, H. Wandt, M. Freund, G. Hess, L. Truemper, V. Diehl, M. Kropff, et al.
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
Blood,
November 1, 2004;
104(9):
2667 - 2674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc.,
May 1, 2004;
15(5):
703 - 711.
[Full Text]
[PDF]
|
|
|
|
|
